Aurobindo Pharma Share Price Surges Over 3% After Subsidiary Lannett Launches Generic Advair Diskus in US

Aurobindo Pharma has taken its first step towards commercialising its inhalation portfolio in the US. Lannett Company LLC, the company's wholly owned step-down subsidiary, has launched a generic version of Advair Diskus in the country. 

The product contains fluticasone propionate and salmeterol inhalation powder and is used in a combination therapy for asthma and chronic obstructive pulmonary disease (COPD).  

First Inhalation Launch in the US 

For Aurobindo, the launch is significant because it is the first product from its inhalation pipeline to be commercialised in the US. The company said the move is part of its effort to build a portfolio of complex and differentiated inhalation products.  

Lannett is handling the launch in the US. The company is a wholly owned subsidiary of Aurobindo Pharma USA, placing the new product within Aurobindo's US business.  

Two Strengths Now Available 

The generic Advair Diskus has launched in two strengths of 100/50 mcg and 250/50 mcg, with both containing the same two active ingredients which are fluticasone propionate and salmeterol.  

The launch gives Aurobindo a commercial product from its inhalation pipeline in the US for the first time. Management has linked the development to its wider focus on differentiated inhalation products.  

Read More: Piramal Finance Share Price in Focus; Secures ₹3,850 Crore Capital with QIP and Promoter Warrants! 

Aurobindo Pharma Share Price Performance  

As of 31 August 2026, at 12:38 PM, Aurobindo Pharma Limited share price is trading at ₹1,697.10 per share, reflecting a surge of 3.15% from the previous trading session. 

Conclusion 

The US launch gives Aurobindo's inhalation pipeline its first commercial product in the market. The company has described it as part of its broader push to develop and commercialise differentiated inhalation products.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.